Regeneron Pharmaceuticals (REGN) has entered into an agreement with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to manufacture and study two antibodies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS). According to the terms of the agreement, HHS will provide up to $8.9M to support packaging and labeling of the antibodies for human use, the preparation and submission of an Investigational New Drug (IND) application with the FDA and a Phase 1 study in healthy volunteers to be conducted by the National Institutes of Health.